A recent study reveals that individuals who come off popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional lifestyle programs.
Published data in a prominent medical journal shows that while obese people frequently drop about a fifth of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users purchasing these treatments should be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment mass within about a year and a half.
Weighing Treatments
The analysis, which reviewed dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
Scientists point out that individuals who lose weight through dieting generally experience a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Experts suggest the way of the drugs explains the heightened rebound.
The injections imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone levels several times higher than normal might result in the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement results in appetite is unsuppressed, making binge eating far more likely."
A Lifelong Condition?
Health authorities suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the likelihood of weight regain, the therapy is often long-term.
This view is reinforced by pharmaceutical companies, who state that the findings "emphasize the chronic character of excess weight," akin to managing diseases like hypertension.
User Testimonies
Users who have discontinued the jabs explain a intense return of cravings.
"I experienced something flipping and you become ravenous," described an individual.
This challenge is compounded if patients have not developed sustainable dietary or behavioural changes during therapy.
Widespread Interest
Recent estimates indicate that millions of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Adoption is greater among females than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and long-term success hinges on combined lifestyle support.
